Immunogen (IMGN) 10.01 $IMGN
ImmunoGen Reports Encouraging Data on Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 3:30PM CST
ImmunoGen (IMGN) presented encouraging data on IMGN529, being evaluated for the treatment of diffuse large B-cell lymphoma and other non-Hodgkin lymphoma subtypes.
IMGN: 10.01 (unch), AMGN: 164.53 (-1.55), SNY: 45.16 (-1.05)
ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition
Business Wire - Sat Dec 06, 11:01AM CST
--Dose finding is ongoing, with the maximum tolerated dose (MTD) not yet established.
IMGN: 10.01 (unch)
Insider Trading Alert - UNT, IMGN And PSXP Traded By Insiders
at The Street - Wed Dec 03, 11:28AM CST
Stocks with insider trader activity include UNT, IMGN and PSXP
PSXP: 60.96 (+0.35), UNT: 30.82 (-0.73), IMGN: 10.01 (unch)
'Mad Money' Lightning Round: You're on Your Own With Tesla
at The Street - Wed Dec 03, 5:00AM CST
Cramer says MasterCard and Visa are heading higher but he's staying away from a 'controversial' Trinity Industries.
TSLA: 207.00 (-1.88), V: 256.78 (-6.34), TSO: 74.41 (+0.14), PPL: 35.02 (-0.30), KGC: 2.96 (-0.10), GOLD: 64.45 (-0.89), TRN: 26.99 (-0.87), IMGN: 10.01 (unch), HFC: 37.33 (-0.46), REGN: 416.44 (-7.91), MA: 84.13 (-3.56), CELG: 114.49 (-2.25)
Cramer's Lightning Round - Power To The PPL (12/2/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 03, 4:46AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday December 2. Bullish Calls: PPL Corporation (NYSE: PPL ): "It is one of my favorites. I like its power." MasterCard (NYSE: MA ): ...
TSLA: 207.00 (-1.88), TSO: 74.41 (+0.14), KGC: 2.96 (-0.10), GOLD: 64.45 (-0.89), PPL: 35.02 (-0.30), TRN: 26.99 (-0.87), IMGN: 10.01 (unch), HFC: 37.33 (-0.46), REGN: 416.44 (-7.91), MA: 84.13 (-3.56), CELG: 114.49 (-2.25)
Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners
at The Street - Tue Dec 02, 7:21PM CST
Bottom fishing in this market has been a disaster, Cramer says.
TSLA: 207.00 (-1.88), BIIB: 344.49 (+2.16), BMRN: 91.52 (-1.38), GOLD: 64.45 (-0.89), IMGN: 10.01 (unch), SDRL: 11.06 (-0.15), HFC: 37.33 (-0.46), LUV: 41.41 (-0.51), CELG: 114.49 (-2.25), V: 256.78 (-6.34), RIG: 16.47 (-0.55), ISIS: 62.32 (+0.45), TSO: 74.41 (+0.14), ESV: 27.04 (-0.80), VALE: 7.19 (-0.07), PPL: 35.02 (-0.30), KGC: 2.96 (-0.10), TRN: 26.99 (-0.87), EOG: 86.37 (-0.49), JCP: 6.38 (+0.29), AAL: 49.97 (-0.56), GM: 31.57 (-0.62), REGN: 416.44 (-7.91), MA: 84.13 (-3.56)
Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer agents
PR Newswire Europe - Wed Nov 26, 7:21PM CST
Ventana Medical Systems, Inc. [http://www.ventana.com/] (Ventana), a member of the Roche [http://www.roche.com/index.htm] Group, today announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC).
IMGN: 10.01 (unch)
ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition
Business Wire - Mon Nov 24, 2:30PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the data presentations on Company and partner experimental therapies to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco, CA.
IMGN: 10.01 (unch)
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 4.33 (+0.07), LXRX: 0.85 (-0.05), IMGN: 10.01 (unch), RGLS: 16.06 (-0.25), ARNA: 3.91 (-0.18)
Global Antibody Drug Conjugate Market Outlook 2018 Edition
M2 - Fri Nov 14, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/m3rq9c/global_antibody) has announced the addition of the "Global Antibody Drug Conjugate Market Outlook 2018 Edition" report to their offering. According to our report, Global Antibody Drug Conjugate Market Outlook 2018, backed by improved understanding and better technology, the ADC market is anticipated to reach around US$ 3 Billion by 2018. For more than a century, the concept of a magic bullet to deliver cytotoxic therapy to the site of tumor has been envisioned, but only recently the technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of ADCETRIS and Kadcyla followed by various ADCs in pipeline highlight the potential for new therapeutic innovations in ADC industry. The report also provides an insight into the key ADCs that are in advanced stage of trial, with Glembatumumab vedotin (Anti-GPNMB ADC) as one of the examples. Further, the report highlights the ADCs with respect to the type of cancer targeted, and drugs used. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place in the ADC space have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones, for the development of ADCs. Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs, difficult upstream and downstream processing, safety considerations, etc., will have to be taken care of. At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Antibody Drug Conjugate (ADC) - An Introduction 4. ADC Market Outlook to 2018 5. ADC Pipeline Analysis 6. Current Status of Potential ADCs in Pipeline 7. Strategic Collaborations in the ADC Industry 8. Drivers and Challenges 9. Competitive Landscape Companies Mentioned - Agensys, Inc. - Immunogen, Inc. - Immunomedics - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/m3...l_antibody
IMMU: 4.58 (-0.09), IMGN: 10.01 (unch)
ImmunoGen, Inc. Again Named One of The Boston Globe's Top Places to Work
Business Wire - Thu Nov 13, 3:00PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received this recognition for the second consecutive year and in three of the last four years.
IMGN: 10.01 (unch)
Earnings Look Back: Immunogen Is Up 11.7% Since Reporting Quarterly Results 2 Weeks Ago (IMGN)
Comtex SmarTrend(R) - Mon Nov 10, 12:31PM CST
17 days ago, on October 24th, 2014, Immunogen (NASDAQ:IMGN) reported its earnings. Analysts, on average, expected a loss of $0.15 per share on sales of $23.6 million. The company actually reported a loss of $0.26 per share on sales of $13.2 million, missing EPS estimates by $0.11 and missing revenue estimates by $10.4 million. Since the company's report, shares of Immunogen have risen from $8.75 to $9.77, representing a gain of 11.7% in the past 17 days.
IMGN: 10.01 (unch)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.57 (+0.01), IMGN: 10.01 (unch), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), OXGN: 1.71 (-0.11), XLRN: 41.77 (+0.29), KPTI: 34.85 (+1.35), NVS: 93.52 (-0.82)
Downtrend Call Working As Immunogen Stock Falls 16.8% (IMGN)
Comtex SmarTrend(R) - Wed Nov 05, 9:47AM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on July 8th, 2014 at $11.08. In approximately 4 months, Immunogen has returned 16.79% as of today's recent price of $9.22.
IMGN: 10.01 (unch)
Why ImmunoGen, Inc. Stock Plunged 13% in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 9:46AM CST
IMGN data by YCharts What: Shares of ImmunoGen , a biopharmaceutical company focused on developing targeted therapies to treat cancer, plunged as much as 13% in October, based on closing price data from S&P Capital IQ , after whiffing...
IMGN: 10.01 (unch)
ImmunoGen: Analysis Of Earnings Miss
CapitalCube - Seeking Alpha - Thu Oct 30, 10:54AM CDT
ImmunoGen just reported its preliminary financial results based on which we provide a unique corporate earnings release based analysis of its performance. Our analysis focuses on the company’s performance for the same quarterly period on a...
IMGN: 10.01 (unch)
15.3% Return Seen to Date on SmarTrend Immunogen Call (IMGN)
Comtex SmarTrend(R) - Wed Oct 29, 9:16AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on July 8th, 2014 at $11.08. In approximately 4 months, Immunogen has returned 15.25% as of today's recent price of $9.39.
IMGN: 10.01 (unch)
Ventana and Immunogen team up in companion diagnostics
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:44AM CDT
IMGN: 10.01 (unch)
ImmunoGen, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 11:42AM CDT
For a drug company with a product on the market, investors have to balance valuations in terms of sales of existing products with the development of new products that will drive future growth. Source: Roche ImmunoGen 's valuation comes...
IMGN: 10.01 (unch)
ImmunoGen Reports Encouraging Data on Cancer Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 3:30PM CST
ImmunoGen (IMGN) presented encouraging data on IMGN529, being evaluated for the treatment of diffuse large B-cell lymphoma and other non-Hodgkin lymphoma subtypes.
IMGN: 10.01 (unch), AMGN: 164.53 (-1.55), SNY: 45.16 (-1.05)
ImmunoGen, Inc. Announces Encouraging IMGN529 Clinical Data Presented at 56th ASH Annual Meeting and Exposition
Business Wire - Sat Dec 06, 11:01AM CST
--Dose finding is ongoing, with the maximum tolerated dose (MTD) not yet established.
IMGN: 10.01 (unch)
Insider Trading Alert - UNT, IMGN And PSXP Traded By Insiders
at The Street - Wed Dec 03, 11:28AM CST
Stocks with insider trader activity include UNT, IMGN and PSXP
PSXP: 60.96 (+0.35), UNT: 30.82 (-0.73), IMGN: 10.01 (unch)
'Mad Money' Lightning Round: You're on Your Own With Tesla
at The Street - Wed Dec 03, 5:00AM CST
Cramer says MasterCard and Visa are heading higher but he's staying away from a 'controversial' Trinity Industries.
TSLA: 207.00 (-1.88), V: 256.78 (-6.34), TSO: 74.41 (+0.14), PPL: 35.02 (-0.30), KGC: 2.96 (-0.10), GOLD: 64.45 (-0.89), TRN: 26.99 (-0.87), IMGN: 10.01 (unch), HFC: 37.33 (-0.46), REGN: 416.44 (-7.91), MA: 84.13 (-3.56), CELG: 114.49 (-2.25)
Cramer's Lightning Round - Power To The PPL (12/2/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Wed Dec 03, 4:46AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday December 2. Bullish Calls: PPL Corporation (NYSE: PPL ): "It is one of my favorites. I like its power." MasterCard (NYSE: MA ): ...
TSLA: 207.00 (-1.88), TSO: 74.41 (+0.14), KGC: 2.96 (-0.10), GOLD: 64.45 (-0.89), PPL: 35.02 (-0.30), TRN: 26.99 (-0.87), IMGN: 10.01 (unch), HFC: 37.33 (-0.46), REGN: 416.44 (-7.91), MA: 84.13 (-3.56), CELG: 114.49 (-2.25)
Jim Cramer's 'Mad Money' Recap: Forget Bargain Losers, Look for the 52-Week Winners
at The Street - Tue Dec 02, 7:21PM CST
Bottom fishing in this market has been a disaster, Cramer says.
TSLA: 207.00 (-1.88), BIIB: 344.49 (+2.16), BMRN: 91.52 (-1.38), GOLD: 64.45 (-0.89), IMGN: 10.01 (unch), SDRL: 11.06 (-0.15), HFC: 37.33 (-0.46), LUV: 41.41 (-0.51), CELG: 114.49 (-2.25), V: 256.78 (-6.34), RIG: 16.47 (-0.55), ISIS: 62.32 (+0.45), TSO: 74.41 (+0.14), ESV: 27.04 (-0.80), VALE: 7.19 (-0.07), PPL: 35.02 (-0.30), KGC: 2.96 (-0.10), TRN: 26.99 (-0.87), EOG: 86.37 (-0.49), JCP: 6.38 (+0.29), AAL: 49.97 (-0.56), GM: 31.57 (-0.62), REGN: 416.44 (-7.91), MA: 84.13 (-3.56)
Ventana announces collaboration to develop companion diagnostics for ImmunoGen's targeted anticancer agents
PR Newswire Europe - Wed Nov 26, 7:21PM CST
Ventana Medical Systems, Inc. [http://www.ventana.com/] (Ventana), a member of the Roche [http://www.roche.com/index.htm] Group, today announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC).
IMGN: 10.01 (unch)
ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition
Business Wire - Mon Nov 24, 2:30PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the data presentations on Company and partner experimental therapies to be made at the upcoming American Society of Hematology (ASH) annual meeting to be held December 6-9, 2014 in San Francisco, CA.
IMGN: 10.01 (unch)
Technical Updates on Biotech Stocks - ImmunoGen, Lexicon Pharma, ZIOPHARM Oncology, Arena Pharma, and Regulus Therapeutics
PR Newswire - Wed Nov 19, 7:40AM CST
Investor-Edge has initiated coverage on the following equities: ImmunoGen Inc. (NASDAQ: IMGN), Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX), ZIOPHARM Oncology Inc. (NASDAQ: ZIOP), Arena Pharmaceuticals Inc. (NASDAQ: ARNA), and Regulus Therapeutics Inc. (NASDAQ: RGLS). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Tuesday, November 18, 2014, the NASDAQ Composite ended at 4,702.44, up 0.67%, the Dow Jones Industrial Average advanced 0.23%, to finish the day at 17,687.82, and the S&P 500 closed at 2,051.80, up 0.51%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 793.40, up 1.58%, with the index also advancing 12.08% in the last one month. Register for your complimentary reports on these five stocks at:
ZIOP: 4.33 (+0.07), LXRX: 0.85 (-0.05), IMGN: 10.01 (unch), RGLS: 16.06 (-0.25), ARNA: 3.91 (-0.18)
Global Antibody Drug Conjugate Market Outlook 2018 Edition
M2 - Fri Nov 14, 8:31AM CST
Research and Markets (http://www.researchandmarkets.com/research/m3rq9c/global_antibody) has announced the addition of the "Global Antibody Drug Conjugate Market Outlook 2018 Edition" report to their offering. According to our report, Global Antibody Drug Conjugate Market Outlook 2018, backed by improved understanding and better technology, the ADC market is anticipated to reach around US$ 3 Billion by 2018. For more than a century, the concept of a magic bullet to deliver cytotoxic therapy to the site of tumor has been envisioned, but only recently the technological advances enabled antibody-drug conjugates to fulfill that dream. The recent approvals of ADCETRIS and Kadcyla followed by various ADCs in pipeline highlight the potential for new therapeutic innovations in ADC industry. The report also provides an insight into the key ADCs that are in advanced stage of trial, with Glembatumumab vedotin (Anti-GPNMB ADC) as one of the examples. Further, the report highlights the ADCs with respect to the type of cancer targeted, and drugs used. Later in the report, strategic activities such as mergers, acquisitions and collaborations that have taken place in the ADC space have been provided. These activities are aimed at combining technologies and capabilities of other companies with inherent ones, for the development of ADCs. Major drivers such as advances in linker technology and patent fencing through ADC development have been discussed. In an attempt to protect their innovative blockbuster drugs, many pharma giants are moving towards ADCs. These moves are going to have a major impact in shaping the ADC market in the coming years. On the other hand, challenges such as the high cost of production of ADCs, difficult upstream and downstream processing, safety considerations, etc., will have to be taken care of. At the end, major players of the ADC market have been discussed. A brief business overview of every player has been provided along with their product and pipeline portfolio and recent developments. A comparative strength and weakness analysis of these players has also been done. Overall, the report will prove to be a complete source of knowledge and analysis for clients and potential investors. Key Topics Covered: 1. Analyst View 2. Research Methodology 3. Antibody Drug Conjugate (ADC) - An Introduction 4. ADC Market Outlook to 2018 5. ADC Pipeline Analysis 6. Current Status of Potential ADCs in Pipeline 7. Strategic Collaborations in the ADC Industry 8. Drivers and Challenges 9. Competitive Landscape Companies Mentioned - Agensys, Inc. - Immunogen, Inc. - Immunomedics - Roche - Seattle Genetics For more information visit http://www.researchandmarkets.com/research/m3...l_antibody
IMMU: 4.58 (-0.09), IMGN: 10.01 (unch)
ImmunoGen, Inc. Again Named One of The Boston Globe's Top Places to Work
Business Wire - Thu Nov 13, 3:00PM CST
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received this recognition for the second consecutive year and in three of the last four years.
IMGN: 10.01 (unch)
Earnings Look Back: Immunogen Is Up 11.7% Since Reporting Quarterly Results 2 Weeks Ago (IMGN)
Comtex SmarTrend(R) - Mon Nov 10, 12:31PM CST
17 days ago, on October 24th, 2014, Immunogen (NASDAQ:IMGN) reported its earnings. Analysts, on average, expected a loss of $0.15 per share on sales of $23.6 million. The company actually reported a loss of $0.26 per share on sales of $13.2 million, missing EPS estimates by $0.11 and missing revenue estimates by $10.4 million. Since the company's report, shares of Immunogen have risen from $8.75 to $9.77, representing a gain of 11.7% in the past 17 days.
IMGN: 10.01 (unch)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.57 (+0.01), IMGN: 10.01 (unch), AMGN: 164.53 (-1.55), LLY: 69.55 (-2.06), ONTX: 3.86 (-0.06), BMY: 58.75 (-0.93), GSK: 42.42 (-0.93), OXGN: 1.71 (-0.11), XLRN: 41.77 (+0.29), KPTI: 34.85 (+1.35), NVS: 93.52 (-0.82)
Downtrend Call Working As Immunogen Stock Falls 16.8% (IMGN)
Comtex SmarTrend(R) - Wed Nov 05, 9:47AM CST
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on July 8th, 2014 at $11.08. In approximately 4 months, Immunogen has returned 16.79% as of today's recent price of $9.22.
IMGN: 10.01 (unch)
Why ImmunoGen, Inc. Stock Plunged 13% in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 9:46AM CST
IMGN data by YCharts What: Shares of ImmunoGen , a biopharmaceutical company focused on developing targeted therapies to treat cancer, plunged as much as 13% in October, based on closing price data from S&P Capital IQ , after whiffing...
IMGN: 10.01 (unch)
ImmunoGen: Analysis Of Earnings Miss
CapitalCube - Seeking Alpha - Thu Oct 30, 10:54AM CDT
ImmunoGen just reported its preliminary financial results based on which we provide a unique corporate earnings release based analysis of its performance. Our analysis focuses on the company’s performance for the same quarterly period on a...
IMGN: 10.01 (unch)
15.3% Return Seen to Date on SmarTrend Immunogen Call (IMGN)
Comtex SmarTrend(R) - Wed Oct 29, 9:16AM CDT
SmarTrend identified a Downtrend for Immunogen (NASDAQ:IMGN) on July 8th, 2014 at $11.08. In approximately 4 months, Immunogen has returned 15.25% as of today's recent price of $9.39.
IMGN: 10.01 (unch)
Ventana and Immunogen team up in companion diagnostics
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 11:44AM CDT
IMGN: 10.01 (unch)
ImmunoGen, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Fri Oct 24, 11:42AM CDT
For a drug company with a product on the market, investors have to balance valuations in terms of sales of existing products with the development of new products that will drive future growth. Source: Roche ImmunoGen 's valuation comes...
IMGN: 10.01 (unch)
